April 16th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Immunotherapy and Targeted Therapy Triplet Active in Microsatellite Stable mCRC
January 27th 2021The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.
Read More
Tweet Chat Recap: Nivolumab Plus Ipilimumab Best Choice for Second-Line Metastatic CRC
January 26th 2021In an interview with Targeted Oncology following a tweet chat, Mark Lewis, MD, discussed the key takeaways from the discussion and highlighted both the role of immunotherapy in metastatic colorectal cancer and the management of toxicities associated with chemoimmunotherapy regimens.
Read More
Health-Related Quality of Life Low in Younger Colorectal Cancer Survivors
January 18th 2021The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.
Read More
TAS-102 Shows OS Benefit With Bevacizumab in mCRC Ineligible for Intensive Therapy
January 17th 2021The frontline combination of trifluridine/tipiracil in combination with bevacizumab demonstrated an overall survival benefit compared with capecitabine and bevacizumab as treatment of patients with unresectable metastatic colorectal cancer who are not eligible for a standard chemotherapy regimen, resulting in a difference of almost 5 months, according to the final analysis of the phase 2 TASCO1 trial.
Read More
Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL
January 16th 2021The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
Read More
Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer
January 15th 2021Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.
Read More
Safety of Pembrolizumab With Capecitabine and Bevacizumab Demonstrated in MSS mCRC
January 15th 2021Immunotherapy with pembrolizumab in combination with capecitabine-based chemotherapy and the VEGF inhibitor bevacizumab, appeared tolerable as treatment of patients with microsatellite stable metastatic colorectal cancer, showing a safety profile that was expected with the drug, results from a phase 2 study show.
Read More
New CRC Screening Recommendations Posted for Adults Aged 45 to 75 Years
October 30th 2020A draft recommendation statement was published by the United States Preventive Services Task Force stating that screening for colorectal cancer should start at the age of 45, according to a press release from the Task Force Bulletin.
Read More
3-Month CAPOX Regimen Appears Less Toxic Than 6-Month Treatment in CRC
October 30th 2020Results of a randomized phase 3 trial demonstrated that the 3-month regimen of adjuvant combination therapy caused significantly less grade 2 or more peripheral sensory neuropathy than the 6-month regimen as treatment of patients with high-risk stage II colorectal cancer, while not affecting the 3-year disease-free survival rate, according to a report in the Annals of Oncology.
Read More
Targeting KRAS in Colorectal Cancer Is an Ongoing Medical Challenge
October 1st 2020Due to the high prevalence of KRAS-mutant colorectal cancer and the fact that many different KRAS variants are found in these tumors, developing treatment for patients with KRAS-mutant colorectal cancer is an area of unmet medical need
Read More
The health-related quality of life had clinically meaningful improvements with pembrolizumab as a first-line therapy for patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer versus standard-of-care chemotherapy, according to new data presented at the ESMO Virtual Congress 2020.
Read More
Eflornithine Plus Sulindac Has Limited Impact on Disease Progression in Familial Polyposis
September 17th 2020The incidence of disease progression in patients with familial adenomatous polyposis was not significantly lower when patients were treated with eflornithine plus sulindac compared with either drug alone.
Read More
Black Patients Experience Lower OS With CRC Liver Metastases Than Others
September 12th 2020Compared to other racial and ethnic groups, Black patients were the least likely to receive chemotherapy or surgical resection for colorectal liver metastases and experienced worse survival, according to a published research paper.
Read More
Liquid Biopsy Assay May Be Predictive of Survival With Rechallenging Anti-EGFR Treatment in mCRC
September 1st 2020RAS status detected in circulating tumor DNA was associated significantly with clinical outcomes when patients with metastatic colorectal cancer were rechallenged with anti-EGFR monoclonal antibody therapy of either cetuximab or panitumumab, according to findings from a clinical study evaluating RAS mutational status in ctDNA using the OncoBEAM RAS CRC test kit in 2 Japanese multicenter, prospective studies.
Read More
Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01
June 29th 2020Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
Watch
Fruquitinib Receives FDA Fast Track Designation for Metastatic Colorectal Cancer
June 18th 2020Fruquitinib was granted Fast Track Designation for the treatment of patients with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy, as well as anti-EGFR therapy for RAS wild-type tumors
Read More
Preventative Measures and Cancer Screening Recommendations Aid Male Population
June 17th 2020"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."
Read More
Survey Identifies Trends and Unmet Needs for Young-Onset Colorectal Cancer
June 9th 2020In an attempt to better understand the critical unmet needs of young survivors of and patients with colorectal cancer, the Colorectal Cancer Alliance launched an annual survey. These latest findings indicate the unique challenges of young-onset CRC and the need to continue improving this treatment landscape.
Read More
Early Data From Tilsotolimod Plus Nivolumab and Ipilimumab Leads to Expansion of MSS-CRC Trial
June 3rd 2020Tilsotolimod has demonstrated innate and adaptive immune activation in multiple tumors. Now, some safety and efficacy data have been reported for the combination of tilsotolimod plus nivolumab and ipilimumab.
Read More
Updated Survival Data from BEACON CRC Lead to More Specific Questions
June 2nd 2020Scott Kopetz, MD, PhD, discusses the next steps following the phase 3 BEACON CRC trial of encorafenib plus cetuximab with or without binimetinib compared with irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E metastatic colorectal cancer.
Watch
HER2+ Colorectal and Gastric/GEJ Cancers Demonstrate Responses to Fam-Trastuzumab Deruxtecan Therapy
May 30th 2020Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer and advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Encorafenib/Cetuximab Combos Sustain OS Benefit in BRAF+ Metastatic Colorectal Cancer
May 30th 2020Encorafenib plus cetuximab with or without binimetinib continued to show an overall survival benefit compared with cetuximab plus irinotecan-based regimens as treatment of patients with BRAF-mutated metastatic colorectal cancer in the updated findings from the phase 3 BEACON CRC clinical trial.
Read More